Close

Stay informed

Drop us your email and we’ll keep you up-to-date on Medicaid issues.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Letter ·

NAMD Warns Against Broadly Defining Pharmaceutical Value-Based Purchasing in Draft PAVE Act

NAMD wrote to Congress expressing concern with draft legislation that would broadly define pharmaceutical value-based purchasing in a manner that could undermine the Medicaid drug rebate program.

Author
Focus Areas
Program Stream

In 2019, Senators Cassidy and Warner introduced the Patient Affordability Value and Efficiency Act, which sought to broadly define pharmaceutical value-based purchasing. In this letter, NAMD warns that such a broad definition would negatively impact fundamental aspects of the Medicaid drug rebate program and increase Medicaid pharmacy benefit spending.

Related resources

Stay Informed

Drop us your email and we’ll keep you up-to-date on Medicaid issues.